Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. Some OSA patients with low arousal threshold wake up prematurely during
an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle
recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this
protocol the investigators will test the effect of DAW2020 administered before sleep on OSA
phenotype traits and OSA severity during sleep.